BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

283 related articles for article (PubMed ID: 26331314)

  • 1. Persistent and recurrent disease in patients with papillary thyroid carcinoma with clinically apparent (cN1), but not extensive, lymph node involvement and without other factors for poor prognosis.
    Furtado Mde S; Rosario PW; Calsolari MR
    Arch Endocrinol Metab; 2015 Aug; 59(4):285-91. PubMed ID: 26331314
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thyroid ablation with 1.1 GBq (30 mCi) iodine-131 in patients with papillary thyroid carcinoma at intermediate risk for recurrence.
    Rosário PW; Calsolari MR
    Thyroid; 2014 May; 24(5):826-31. PubMed ID: 24283207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Can patients with papillary thyroid carcinoma and low postoperative thyroglobulin in the presence of clinically apparent lymph node metastases (cN1) be spared from radioiodine?
    Rosario PW; Mourão GF; Calsolari MR
    Endocrine; 2020 Dec; 70(3):552-557. PubMed ID: 32653994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term results of ablation with low radioiodine activity in patients with papillary thyroid carcinoma and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Oct; 37(10):1024-9. PubMed ID: 27306852
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low postoperative nonstimulated thyroglobulin as a criterion for the indication of low radioiodine activity in patients with papillary thyroid cancer of intermediate risk 'with higher risk features'.
    Rosario PW; Mourão GF; Calsolari MR
    Clin Endocrinol (Oxf); 2016 Sep; 85(3):453-8. PubMed ID: 26801644
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low postoperative nonstimulated thyroglobulin as a criterion to spare radioiodine ablation.
    Mourão GF; Rosario PW; Calsolari MR
    Endocr Relat Cancer; 2016 Jan; 23(1):47-52. PubMed ID: 26503963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk factors for recurrence of papillary thyroid carcinoma with clinically node-positive lateral neck.
    Lee CW; Roh JL; Gong G; Cho KJ; Choi SH; Nam SY; Kim SY
    Ann Surg Oncol; 2015 Jan; 22(1):117-24. PubMed ID: 25034816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reoperative lymph node dissection for recurrent papillary thyroid cancer and effect on serum thyroglobulin.
    Hughes DT; Laird AM; Miller BS; Gauger PG; Doherty GM
    Ann Surg Oncol; 2012 Sep; 19(9):2951-7. PubMed ID: 22526913
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Patients with Papillary Thyroid Carcinoma at Intermediate Risk of Recurrence According to American Thyroid Association Criteria Can Be Reclassified as Low Risk When the Postoperative Thyroglobulin Is Low.
    Rosario PW; Furtado Mde S; Mourão GF; Calsolari MR
    Thyroid; 2015 Nov; 25(11):1243-8. PubMed ID: 26359309
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The utility of lymph node mapping sonogram and thyroglobulin surveillance in post thyroidectomy papillary thyroid cancer patients.
    Miah CF; Zaman JA; Simon M; Davidov T; Trooskin SZ
    Surgery; 2014 Dec; 156(6):1491-6; discussion 1496-7. PubMed ID: 25456939
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative stimulated thyroglobulin of less than 1 ng/ml as a criterion to spare low-risk patients with papillary thyroid cancer from radioactive iodine ablation.
    Rosario PW; Mineiro Filho AF; Prates BS; Silva LC; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1140-3. PubMed ID: 23050786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
    Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
    Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human TSH versus thyroid hormone withdrawal in adjuvant therapy with radioactive iodine of patients with papillary thyroid carcinoma and clinically apparent lymph node metastases not limited to the central compartment (cN1b).
    Rosario PW; Mourão GF; Calsolari MR
    Arch Endocrinol Metab; 2017; 61(2):167-172. PubMed ID: 28226001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cervical Lymph Node Metastases of Papillary Thyroid Carcinoma, in the Central and Lateral Compartments, in Children and Adolescents: Predictive Factors.
    Spinelli C; Tognetti F; Strambi S; Morganti R; Massimino M; Collini P
    World J Surg; 2018 Aug; 42(8):2444-2453. PubMed ID: 29383423
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Occult Contralateral Lateral Lymph Node Metastases in Unilateral N1b Papillary Thyroid Carcinoma.
    Bohec H; Breuskin I; Hadoux J; Schlumberger M; Leboulleux S; Hartl DM
    World J Surg; 2019 Mar; 43(3):818-823. PubMed ID: 30465086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of adjuvant therapy with 3.7 GBq radioactive iodine in intermediate-risk patients with 'higher risk features' and predictive value of postoperative nonstimulated thyroglobulin.
    Rosario PW; Mourão GF; Calsolari MR
    Nucl Med Commun; 2016 Nov; 37(11):1148-53. PubMed ID: 27341413
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine.
    Rosario PW; Mourão GF
    Endocrine; 2022 Jun; 76(3):671-676. PubMed ID: 35347578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Value of diagnostic radioiodine whole-body scanning after initial therapy in patients with differentiated thyroid cancer at intermediate and high risk for recurrence.
    Rosario PW; Furtado Mde S; Mineiro Filho AF; Lacerda RX; Calsolari MR
    Thyroid; 2012 Nov; 22(11):1165-9. PubMed ID: 23050784
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Postoperative recurrence of papillary thyroid carcinoma with lymph node metastasis.
    Liu FH; Kuo SF; Hsueh C; Chao TC; Lin JD
    J Surg Oncol; 2015 Aug; 112(2):149-54. PubMed ID: 26175314
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment for microcarcinoma of the thyroid--clinical experience.
    Küçük NO; Tari P; Tokmak E; Aras G
    Clin Nucl Med; 2007 Apr; 32(4):279-81. PubMed ID: 17413573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.